Impact of the AT(2) Receptor Agonist C21 on Blood Pressure and Beyond

Sebastien Foulquier, U. Muscha Steckelings, Thomas Unger*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Web of Science)
28 Downloads (Pure)

Abstract

It is now widely accepted that the angiotensin AT(2) receptor (AT(2)R) plays an important protective role during pathophysiologic conditions, acting as a repair system. The development of the first selective nonpeptide AT(2)R agonist C21 accelerated our understanding of AT(2)R-mediated protective signaling and actions. This article reviews the impact of C21 on blood pressure in normotensive and hypertensive animal models. Although C21 does not act as a classical antihypertensive drug, it could be useful in preventing hypertension-induced vascular and other end organ damages via anti-apoptotic, anti-fibrotic and anti-inflammatory actions. In particular, a strong body of evidence started to emerge around its anti-inflammatory feature. This property should be further investigated for potential clinical indications in cardiovascular diseases and beyond.
Original languageEnglish
Pages (from-to)403-409
JournalCurrent Hypertension Reports
Volume14
Issue number5
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Hypertension
  • Blood pressure
  • Angiotensin
  • AT(2)R
  • Renin-angiotensin system
  • RAS
  • Compound 21
  • C21
  • Inflammation
  • Antihypertensive drug therapy

Cite this